TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Age 18 years or older at admission date to the hospital;~2. Received four (4) or more consecutive IV doses of Zinforo® in usual care on or before 31-May-2019; and~3. Admitting diagnosis to the hospital was either CAP or cSSTI.~Exclusion criteria:~1. Patients who were participating in an interventional clinical trial during the same hospital admission in which Zinforo® was administered;~2. Patients whose hospital medical records are missing documentation of the diagnostic criteria for either cSSTI or CAP;~3. Patients whose hospital medical records are missing details of dosing with Zinforo®;~4. Patients whose hospital medical records are missing information on the success/failure of Zinforo® treatment and the reason why treatment was discontinued; and~5. Patients whose hospital medical records are missing discharge date and status information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zinforo Treated (Type: None): Only those Adults treated with this treatment for CAP or cSSTi

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TBE Seropersistence up to 10 Years After First Booster in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects who participated in the first and second precursor studies will be eligible for participation in this study if:~* they understand the nature of the study, agree to its provisions and provide written informed consent~* they received the first booster vaccination with FSME-IMMUN 0.5ml during the first precursor study and did not receive a second booster vaccination in the second precursor study~* blood was drawn after their first booster vaccination in the first precursor study~Exclusion Criteria:~Subjects will be excluded from participation in this study if they:~* received any TBE vaccination since their first booster vaccination with FSME-IMMUN 0.5ml~* have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese B-encephalitis) since their first booster vaccination with FSME-IMMUN 0.5ml~* are known to be HIV positive since their first booster vaccination with FSME-IMMUN 0.5ml~* have a known or suspected problem with drug or alcohol abuse

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Seropersistence evaluation + 2nd booster vaccination (Type: EXPERIMENTAL): Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Technology to Extend Clinic-based Counseling for HIV+s in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older;~* HIV positive;~* On ART for at least six months;~* Reported alcohol use in the prior year at clinic entry;~* Fluency in Runyakole;~* Living within two hours travel time from the clinic;~* Owning or having daily access to a cell phone;~* Screening positive on the AUDIT-C~Exclusion Criteria:~* Plans to move out of the catchment area within 6 months;~* Unable to provide informed consent.~* Participation in another research study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Live Phone Call Booster Arm (Type: EXPERIMENTAL): The live phone call arm will include in-person counseling during 2 quarterly clinic visits plus live booster phone calls every three weeks in the interim.
- Technology Booster Arm (Type: EXPERIMENTAL): The technology booster arm will include in-person counseling during 2 quarterly clinic visits plus tech (choice of SMS or IVR) boosters once to twice weekly in the interim.
- Standard of Care (SOC) Arm (Type: NO_INTERVENTION): The standard of care (SOC) control (brief unstructured advice, with a wait-listed intervention).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ALOFT - Aliskiren Observation of Heart Failure Treatment: Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of diagnosis or currently have high blood pressure~* Stable heart failure (NYHA Class 2-4) for at least 1 month before study entry. Subject should be on a stable dose regimen of heart failure medication.~* Brain natriuretic peptide (BNP) \> 150 pg/ml at baseline (to be evaluated by physician at first visit)~Exclusion Criteria:~* Previous treatment with aliskiren~* High blood pressure due to secondary reasons or constant low blood pressure (systolic \< 90 mmHg)~* History of heart attack or coronary bypass surgery in the past 6 months~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The hospitalized patient was administered Polyoxidonium, according to the instruction for medical usage in complex with Russian MoH guidance for treatment of COVID-19.~2. Verified coronavirus disease COVID-19, and at least one of the following:~   * severe disease: mechanical ventilation or oxygen supply required with blood oxygen saturation (SpO2) ≤ 94% on room air or tachypnea, respiratory rate ≥ 24 breaths per minute,~  * mild-moderate disease: SpO2 \> 94% on room air or respiratory rate \< 24 breaths per minute.~3. The patient signed an Informed Consent form for participation in this study.~4. The patient can understand all protocol requirements, perform the study procedures, and agree to all limitations specified in the protocol.~5. Male and female patients from 18 years of age.~6. Confirmed diagnosis of coronavirus disease (COVID-19): laboratory-confirmed Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR), or other commercial or public health assay in any specimen prior to inclusion.~Exclusion Criteria:~1. Pregnancy or breastfeeding.~2. Pathological condition that the study doctor considers significant enough to prevent enrolment of this patient.~3. Participation in any clinical study within 30 days before the Informed Consent form provided.~4. Hypersensitivity and/or intolerability to any ingredient of the investigational product.~5. Acute or chronic renal failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Adult patients hospitalized with COVID-19 (Type: None): Patients eligible for enrollment into the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Chinese male and female patients with proven diagnosis of type 2 diabetes mellitus treated with diet and exercise only or on a maximum of two oral antidiabetic agents except thiazolidinediones with at least one agent taken at 50% of its maximum dose or less, unchanged for at least 12 weeks before randomization~2. Glycosylated haemoglobin A1(HbA1c)\<=8.5% and \>=7.0% at screening,age\>=21 and age\<=70 years (male and female patients),BMI\>=19 and \<=40 kg/m2~3. Signed and dated written informed consent by date of Visit 1 in accordance with GCP and local legislation.~Exclusion criteria:~1. Patient who did not discontinue the antidiabetic treatment with insulin or glitazones, DPP-IV at least before 12 weeks before randomization~2. Uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast at screening visit~3. Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia and medically treated hypertension, such as:~4 Any late stage complication of diabetes (e.g. retinopathy, polyneuropathy, vegetative disorders, diabetic foot) 5 Renal insufficiency (calculated creatinine clearance \< 80 ml/min/1.73m²) 6 Cardiac insufficiency NYHA II-IV, myocardial infarction, other known cardiovascular diseases including hypertension \> 160/95mmHg (measured at training visit and each of the timepoints of Day -1), stroke and TIA 7 Neurological disorders (such as epilepsy) or psychiatric disorders 8 Acute or relevant chronic infections (e.g. HIV, repeated urogenital infections) 9 Any gastrointestinal, hepatic, respiratory, endocrine or immunological disorder 10. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) 11. A marked baseline prolongation of QT/QTc interval (e.g., ECG demonstration of a QTc interval \>450 ms ) at screening visit

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BI10773 low dose Per Os(p.o.) (Type: EXPERIMENTAL): patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo
- Placebo (Type: PLACEBO_COMPARATOR): patient to receive two placebos
- BI10773 high dose Per Os(p.o.) (Type: EXPERIMENTAL): patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All Diagnostic Statistical Manual, Fifth edition, (DSM-5) diagnoses that included a psychosis spectrum disorder~Exclusion Criteria:~* those lacking symptoms of psychosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: None

Study Arms:
- Younger participants (Type: None): Participants were adults ages19 to 29 years who recieved CBT and 10 minutes of Mindfulness Training and practice in group therapy.
- Older participants (Type: None): Participants were adults ages 30-54 years who received CBT and 10 minutes of Mindfulness Training and practice in group therapy.
- Treatment As Usual (TAU) (Type: None): . Participants in the Treatment As Usual (TAU) group had Cognitive Behavioral Therapy and education about the mindfulness process, but no practice of the mindfulness technique as a group.
- TAU plus mindfulness practice (Type: None): Participants in the TAU plus Mindfulness Practice had Cognitive Behavioral Therapy (CBT) and 10 minutes of mindfulness practice in group therapy sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders aged from 1 month up to less than 18 years at the time of enrolment~* Patients affected by any hereditary haemoglobinopathy requiring chronic transfusion therapy and chelation, including but not limited to thalassemia syndromes and sickle cell disease~* Patients on current treatment with deferoxamine (DFO) or DFX or DFP in a chronic transfusion program receiving at least 150 mL/kg/year of packed red blood cells (corresponding approximately to 12 transfusions);~* For patients naïve to chelation treatment: patients that have received at least 150 mL/kg of packed red blood cells (corresponding to approximately 12 transfusions) in a chronic transfusion program and with serum ferritin levels ≥ 800 ng/mL;~* Until availability of results from the PK Study (Study DEEP-1, EudraCT n. 2012-000658-67) for patients aged from 1 month to less than 6 years: known intolerance or contraindication to DFO;~* Written informed consent and patient's informed assent, relating to his/her comprehension abilities and level of maturity~Exclusion Criteria:~* Patients with intolerance or known contraindication to either DFP or DFX~* Patients receiving DFX at a dose \> 40 mg/kg/day or DFP at a dose \> 100 mg/kg/day at screening~* Platelet count \<100.000/mm3 during the run-in phase~* Absolute neutrophils count \<1.500/mm3 during the run-in phase~* Hb levels lower than 8g/dL during the run-in phase~* Evidence of abnormal liver function~* Iron overload from causes other than transfusional haemosiderosis~* Severe heart dysfunction secondary to iron overload~* Serum creatinine level \> ULN (Upper Limit of Normal) for age during the run-in phase~* History of significant medical or psychiatric disorder~* The patient has received another investigational drug within 30 days prior to this clinical trial~* Fever and other signs/symptoms of infection in the 10 days before baseline assessment~* Concomitant use of trivalent cation-dependent medicinal products such as aluminium-based antacids~* Positive test for β-HCG (Human chorionic gonadotropin) and lactating female patients

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Deferiprone (Type: EXPERIMENTAL): 75-100 mg/kg/day seven days per week
- Deferasirox (Type: ACTIVE_COMPARATOR): 20 to 40 mg/kg/day seven days per week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
PAPP-A2 deficient~Inclusion Criteria:~* Defect in PAPP-A2 (heterozygous or homozygous mutation)~Exclusion Criteria:~* None~Healthy Volunteers~Inclusion Criteria:~* Between the ages of 18 and 30~* In general good health~Exclusion Criteria:~* Any medications (with the exception of contraceptives)~* Pregnancy

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PAPP-A2 deficient patients (Type: EXPERIMENTAL): Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 to 75~* BMI greater than or equal to 25~* HbA1c greater than or equal to 7.5% and less than or equal to 10.5%~* Type 2 Diabetes Mellitus and on stable dose of oral metformin~* Agree to conduct home-based (fasted) blood glucose testing as directed~Exclusion Criteria:~* Clinically significant abnormalities in medical history or physical exam~* Show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results~* History of renal transplantation or renal dialysis~* History of liver disease~* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening~* Use of oral anti-diabetic medication other than metformin within 3 months of screening~* History of diabetic ketoacidosis~* Any other significant illness or condition that may interfere with the patient participating or completing the study~* Inability or unwillingness to comply with protocol or study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-GCGRRx Dose Level 1 (Type: EXPERIMENTAL): ISIS-GCGRRx Dose Level 1
- ISIS-GCGRRx Dose Level 2 (Type: EXPERIMENTAL): ISIS-GCGRRx Dose Level 2
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* The subject must have had her most recent surgical and - if available - histological, diagnosis of pelvic endometriosis up to 10 years before screening.~* The subject has moderate to severe endometriosis-associated pain during the screening period.~* The subject has regular menstrual cycles.~* The subject has a BMI ≥ 18 kg/m2 at the screening visit.~Key Exclusion Criteria:~* The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.~* The subject had an interventional surgery for endometriosis performed within a period of 60 days before screening.~* The subject did not respond to prior treatment with gonadotropin releasing hormone (GnRH) agonists or GnRH antagonists for endometriosis.~* The subject has a history of, or known osteoporosis or other metabolic bone disease.~* The subject has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic / therapy, or that would interfere with the assessment of endometriosis related pain.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- OBE2109 50 mg (Type: EXPERIMENTAL): None
- OBE2109 75mg fixed dose (FD) (Type: EXPERIMENTAL): None
- OBE2109 75mg titrated dose (TD) (Type: EXPERIMENTAL): None
- OBE2109 100mg (Type: EXPERIMENTAL): None
- OBE2109 200 mg (Type: EXPERIMENTAL): None
- Placebo / OBE2109 100mg (Type: PLACEBO_COMPARATOR): Participants received placebo for the first 12 weeks and were then crossed-over to active treatment with OBE2109 100mg for a further 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete